The impact of hip and knee osteoarthritis on the subsequent risk of incident diabetes: a population-based cohort study

Kendzerska, Tetyana; King, Lauren; Lipscombe, Lorraine L.; Croxford, Ruth; Stanaitis, I.; Hawker, Gillian

doi:10.1007/s00125-018-4703-2

Cited by 36 publications

(48 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another important aspect to be considered is the potential reverse association between osteoarthritis and metabolic syndrome, i.e. that osteoarthritis is a significant independent predictor for developing diabetes mellitus [17]. Furthermore, hip and knee osteoarthritis are also associated with increased cardiovascular risk [34], due to the limited mobility of osteoarthritic patients [14,17,34].…”

Section: Hip Degenerationmentioning

confidence: 99%

See 1 more Smart Citation

Association between metabolic syndrome and hip osteoarthritis in middle-aged men and women from the general population

Walter

Wintermeyer²,

Klinger

et al. 2020

PLoS ONE

View full text Add to dashboard Cite

Objective To investigate the impact of metabolic syndrome and its components on osteoarthritis of the hip joints compared to a healthy cohort in the KORA MRI-study. Methods Randomly selected men and women from the general population were classified as having metabolic syndrome, defined as presence of central obesity plus two of the following four components: elevated blood pressure (BP), elevated fasting glucose, elevated triglycerides (TG) and low HDL-cholesterol (HDL-c), or as controls without metabolic syndrome. Therefore, each subject underwent detailed assessment of waist circumference as well as fasting glucose, systolic and diastolic BP, TG, and HDL-c concentrations as well as a full-body MR scan. MR measurements were performed on a 3 Tesla scanner (Magnetom Skyra, Siemens) including a dual-echo Dixon and a T2 SS-FSE sequence for anatomical structures. In order to quantify osteoarthritis of the hip, assessment was performed by two independent, experienced radiologists for joint gap narrowing, osteophytic lipping and subchondral changes (e.g. sclerosis, pseudocysts). Associations between metabolic syndrome components and hip degeneration were estimated by logistic regression models providing odds ratios. Results Among 354 included participants (mean age: 56.1 ± 9.2 years; 55.4% male), 119 (34%) had metabolic syndrome, while 235 (66%) were part of the control group. Except for elevated

show abstract

Section: Hip Degenerationmentioning

confidence: 99%

“…knee or hip joint), such as age, nutritional habits or central obesity, which are concomitantly responsible for causing or worsening diabetes [1,4,8,10,15,16]. Yet, osteoarthritis and metabolic syndrome may simply be co-existing through these common risk factors [9,17].…”

Section: Introductionmentioning

confidence: 99%

Association between metabolic syndrome and hip osteoarthritis in middle-aged men and women from the general population

Walter

Wintermeyer²,

Klinger

et al. 2020

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Blinding may not be necessary when mortality is used as an endpoint in a confirmatory trial because bias may be less likely. Given the increased prevalence and incidence of diabetes in individuals with lower limb arthritis, with a large proportion (37e46%) attributable to walking disability 21 , the incidence or worsening of diabetes and step counts or mobility data (made increasingly available through use of wearable devices) are examples of the types of real-world data that could contribute to a real-world efficacy indication for a DMOAD.…”

Section: Pain-lowering-anabolic-profilementioning

confidence: 99%

Proposed study designs for approval based on a surrogate endpoint and a post-marketing confirmatory study under FDA's accelerated approval regulations for disease modifying osteoarthritis drugs

Kraus

Simon²,

Katz

et al. 2019

Osteoarthritis and Cartilage

View full text Add to dashboard Cite

s u m m a r yIn 1992, the Food and Drug Administration (FDA) instituted the accelerated approval regulations that allow drugs or biologics for serious conditions that fill an unmet medical need to be approved on the basis of a surrogate endpoint or an intermediate clinical endpoint. The current definition of a serious condition includes chronic disabling conditions, such as osteoarthritis (OA), and thereby provides expanded opportunities for the use of biomarkers for regulatory approval of drugs for OA. The use of surrogates or intermediate clinical endpoints for initial regulatory approval of a drug or biologic requires confirmation in a post-marketing study of a drug effect on a clinically relevant outcome, such as on how a patient feels, functions or survives. Current FDA guidance requires that the post-marketing approval (PMA) study be ongoing during the time of initial drug approval. This white paper arose out of the need to brainstorm trial designs that might be suitable for PMA of drugs initially approved, on the basis of a surrogate or intermediate clinical endpoint, for treatment of OA to alter disease progression, abnormal function or pathological changes in the morphology of the joint. In this white paper we define the concept and regulations regarding accelerated approval and propose two major study design scenarios for PMA trials in OA. The long-term goal is to discuss and refine these designs in consultation with regulatory agencies in order to facilitate development of drugs to fill the large unmet need in OA.

show abstract

“…These associations were even more pronounced in young diabetic subjects with hand OA, which seem more prone to develop the erosive subtype of the disease . Surprisingly, the relationship between T2D and OA appears to be bidirectional: In a cohort study, joint pain and reduced mobility in the knee and hip leading to a sedentary lifestyle have demonstrated to significantly promote the development of T2D in patients older than 55 years of age …”

Section: Osteoarthritis and Type 2 Diabetesmentioning

confidence: 99%

“…29 Surprisingly, the relationship between T2D and OA appears to be bidirectional: In a cohort study, joint pain and reduced mobility in the knee and hip leading to a sedentary lifestyle have demonstrated to significantly promote the development of T2D in patients older than 55 years of age. 30 Classically, age-related joint degeneration and biomechanical overload due to overweight have been considered as the main risk factors promoting OA in diabetic subjects. However, recent developments in the knowledge of OA and T2D have introduced the role of systemic factors, including dyslipidaemia, hyperglycaemia, and inflammation (reunited in the so-called metabolic syndrome) that may directly induce OA.…”

Section: Osteoarthritis and Type 2 Diabetesmentioning

confidence: 99%

Osteoarthritis and type 2 diabetes: From pathogenetic factors to therapeutic intervention

Cannata

Vadalà

Ambrosio

et al. 2019

Diabetes Metabolism Res

View full text Add to dashboard Cite

Summary Over the last decades, osteoarthritis (OA) and type 2 diabetes (T2D) prevalence increased due to the global ageing population and the pandemic obesity. They currently affect a substantial part of the Western world population and are characterized by enhancing the risk of disability and reduction of quality of life. OA is a multifactorial condition whose development derives from the interaction between individual and environmental factors: The best known primarily include age, female gender, genetic determinants, articular biomechanics, and obesity (OB). Given the high prevalence of OA and T2D and their association with OB and inflammation, several studies have been conducted to investigate the causative role of biological characteristics proper to T2D on the development of OA. This review aims to analyse the relationship between of OA and T2D, in order to explain the pathophysiological drivers of the degenerative process and to delineate possible targets to which appropriate treatments may be addressed in the near future.

show abstract

The impact of hip and knee osteoarthritis on the subsequent risk of incident diabetes: a population-based cohort study

Cited by 36 publications

References 39 publications

Association between metabolic syndrome and hip osteoarthritis in middle-aged men and women from the general population

Association between metabolic syndrome and hip osteoarthritis in middle-aged men and women from the general population

Proposed study designs for approval based on a surrogate endpoint and a post-marketing confirmatory study under FDA's accelerated approval regulations for disease modifying osteoarthritis drugs

Osteoarthritis and type 2 diabetes: From pathogenetic factors to therapeutic intervention

Contact Info

Product

Resources

About